Navulizumab in combination with fluorouracil-based and oxaliplatin-based chemotherapy can be a first-line treatment option for patients with advanced HER-2 negative gastric cancer with PD-L1 CPS ≥ 5. The gene discussed is ERBB2; the disease is gastric cancer.